712 related articles for article (PubMed ID: 25797867)
1. Bridging the osteoporosis treatment gap: performance and cost-effectiveness of a fracture liaison service.
Yates CJ; Chauchard MA; Liew D; Bucknill A; Wark JD
J Clin Densitom; 2015; 18(2):150-6. PubMed ID: 25797867
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.
Majumdar SR; Lier DA; Hanley DA; Juby AG; Beaupre LA;
Osteoporos Int; 2017 Jun; 28(6):1965-1977. PubMed ID: 28275838
[TBL] [Abstract][Full Text] [Related]
4. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
5. Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis.
Kingkaew P; Maleewong U; Ngarmukos C; Teerawattananon Y
Value Health; 2012; 15(1 Suppl):S20-8. PubMed ID: 22265062
[TBL] [Abstract][Full Text] [Related]
6. Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
Ström O; Jönsson B; Kanis JA
Osteoporos Int; 2013 Apr; 24(4):1491-502. PubMed ID: 23224141
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.
Jönsson B; Ström O; Eisman JA; Papaioannou A; Siris ES; Tosteson A; Kanis JA
Osteoporos Int; 2011 Mar; 22(3):967-82. PubMed ID: 20936401
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
Moriwaki K; Mouri M; Hagino H
Osteoporos Int; 2017 Jun; 28(6):1939-1950. PubMed ID: 28265718
[TBL] [Abstract][Full Text] [Related]
9. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
Hiligsmann M; Bruyère O; Reginster JY
Bone; 2010 Feb; 46(2):440-6. PubMed ID: 19716940
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of a fracture liaison service--a real-world evaluation after 6 years of service provision.
Yong JH; Masucci L; Hoch JS; Sujic R; Beaton D
Osteoporos Int; 2016 Jan; 27(1):231-40. PubMed ID: 26275439
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
Chau D; Becker DL; Coombes ME; Ioannidis G; Adachi JD; Goeree R
J Med Econ; 2012; 15 Suppl 1():3-14. PubMed ID: 23035625
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
Goeree R; Blackhouse G; Adachi J
Curr Med Res Opin; 2006 Jul; 22(7):1425-36. PubMed ID: 16834841
[TBL] [Abstract][Full Text] [Related]
14. Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
Berto P; Maggi S; Noale M; Lopatriello S
Aging Clin Exp Res; 2010 Apr; 22(2):179-88. PubMed ID: 20145427
[TBL] [Abstract][Full Text] [Related]
15. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision.
McLellan AR; Wolowacz SE; Zimovetz EA; Beard SM; Lock S; McCrink L; Adekunle F; Roberts D
Osteoporos Int; 2011 Jul; 22(7):2083-98. PubMed ID: 21607809
[TBL] [Abstract][Full Text] [Related]
16. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women.
Yoshimura M; Moriwaki K; Noto S; Takiguchi T
Osteoporos Int; 2017 Feb; 28(2):643-652. PubMed ID: 27743068
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
Schousboe JT; Taylor BC; Fink HA; Kane RL; Cummings SR; Orwoll ES; Melton LJ; Bauer DC; Ensrud KE
JAMA; 2007 Aug; 298(6):629-37. PubMed ID: 17684185
[TBL] [Abstract][Full Text] [Related]
18. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Tosteson AN; Burge RT; Marshall DA; Lindsay R
Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
[TBL] [Abstract][Full Text] [Related]
19. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
[TBL] [Abstract][Full Text] [Related]
20. Fracture liaison service in a non-regional orthopaedic clinic--a cost-effective service.
Ahmed M; Durcan L; O'Beirne J; Quinlan J; Pillay I
Ir Med J; 2012 Jan; 105(1):24, 26-7. PubMed ID: 22397210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]